Morton Jessica Ann
Known title: VP, Gen Counsel, SecretaryCIK: 0001968573
Associated companies
Transaction History
| ROG | ▼ Sell | Tax Withholding | 248 | $26K | 3/11/2026 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 427 | $46K | 2/28/2026 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 374 | $42K | 2/19/2026 | View on chart |
| ROG | ▲ Buy | Grant | 3,451 | $0 | 2/18/2026 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 240 | $18K | 3/11/2025 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 365 | $33K | 2/19/2025 | View on chart |
| ROG | ▲ Buy | Grant | 3,913 | $0 | 2/12/2025 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 260 | $31K | 3/11/2024 | View on chart |
| ROG | ▲ Buy | Grant | 2,990 | $0 | 2/19/2024 | View on chart |
| ROG | ▲ Buy | Grant | 2,305 | $0 | 3/11/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Roche presents new Phase III data and FDA approval
Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.
Roche presents new Phase III data and FDA approval. Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.